Posts by: Magdalena Kegel

Magdalena Kegel

Magdalena holds an MSc in Pharmaceutical Bioscience and an interdisciplinary PhD merging the fields of psychiatry, immunology and neuropharmacology. Her previous research focused on metabolic and immunologic changes in psychotic disorders. She is now focusing on science writing, allowing her to culture her passion for medical science and human health.

May 8, 2017

Phase 1 Trial of Ovarian Cancer Therapy Mirvetuximab Supports Phase 3 Study

News

Results from a Phase 1 clinical trial of mirvetuximab soravtansine (IMGN853) as a treatment for chemotherapy-resistant ovarian cancer and other malignancies have propelled the therapy into a Phase 3 trial. ... Read more

April 17, 2017April 17, 2017

Syros’ SY-1365 Displays Punch Against Ovarian Cancer, Studies Show

News

Syros Pharmaceuticals’ investigational compound SY-1365 showed potent anticancer activity in cell and animal models of ovarian cancer, giving the company momentum to move toward the Phase 1 trial it plans later ... Read more

April 5, 2017April 5, 2017

New Imaging Method May Identify Ovarian Cancer Patients Likely to Benefit From PARP Inhibitors

News

A new imaging method aims to identify ovarian cancer patients most likely to benefit from treatment with PARP-1 inhibitors — a drug class being developed for people with mutations in ... Read more

March 13, 2017

Study Analyzes Use of Circulating Tumor Cells as Prognostic Marker in Ovarian Cancer

News

Most women with epithelial ovarian cancer have circulating tumor cells, and among those who recently received their cancer diagnosis, the more such cells they had, the shorter their survival times, ... Read more

March 1, 2017

Trial Therapy’s Potential to Prevent Ovarian Cancer Relapses Supported by Mouse Study

News

An investigational drug that boosts the response of natural killer (NK) cells — key players of first-line immune defenses — was recently shown to effectively decrease ovarian tumors in a ... Read more

February 24, 2017

Lynparza Long-Term Responders Likely to have Deficient DNA Repair

News

Long-term, progression-free survival in women with ovarian cancer treated with Lynparza (olaparib) is likely linked to deficient DNA repair mechanisms, particularly those caused by mutations in the BRCA genes. In ... Read more

February 3, 2017

New Gene Insights May Explain Ovarian Cancer in Absence of BRCA Mutations

News

A gene previously thought to contribute to ovarian cancer by disrupting the well-known BRCA genes, is driving cancer growth independently of the other factors, new research shows. The discovery is ... Read more

November 11, 2016November 11, 2016

RNA-blocking Nanotherapy for Ovarian Cancer Boosts Chemotherapy Response in Mice

News

A lucky circumstance led scientists, working in mice, to discover that nanoparticle-delivered siRNA blockers of a molecule found in ovarian cancer can dramatically improve response to chemotherapy. The siRNA molecules ... Read more

August 19, 2016August 19, 2016

Lack of Genetic Testing in Ovarian Cancer Due to Slow Changes in Healthcare, Writer Says

News

A blog post by Emma Smith at Cancer Research UK asks why all women diagnosed with ovarian cancer aren’t being genetically tested for mutations in the BRCA1 and BRCA2 genes — a ... Read more